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Background: Although continuous positive airway pressure (CPAP) is effective in treating
obstructive sleep apnoea (OSA), inadequate adherence remains a major cause of treatment
failure. This study aimed to determine long term adherence to auto adjusting-CPAP (APAP)
and its influencing factors including the role of initial compliance.
Methods: Eighty-eight male patients with newly diagnosed moderate/severe OSA were
included. After initiation of APAP treatment, patients had periodic follow-up appointments
at 2 weeks, 6 months and then annually for at least 5 years. Patient’s compliance to therapy
was assessed in each appointment and predictors to treatment abandonment and poor compli-
ance were evaluated.
Results: The studied population had a mean age of 53.8 years and mean apnoeaehypopnoea
index of 52.71/h.
The mean time of follow-up was 5.2 (1.6) years, during that time 22 (25%) patients aban-
doned APAP, those who maintained treatment had good compliance to it since 94% of them
used it more than 4 h/day for at least 70% of days.
A significant negative association was found between age, % of days and mean time of APAP
use on 12th day and 6th month and the risk of abandoning. APAP use lower than 33% and 57% of
days at 12th day and 6th month, respectively had high specificity (w100%) to detect treatment
abandonment.a@gmail.com, mafalda_vanzeller@hotmail.com (M. van Zeller).
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5-Years APAP adherence in OSA patients 2047Conclusions: the majority of patients adheres to long term APAP treatment and has good
compliance after 5-years of follow-up. Age and initial compliance (% days of use and mean
hour/day) have the ability to predict future adherence, as soon as 12 days and 6 months after
initiation.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnoea (OSA) is a disorder characterized
by recurrent episodes of partial or complete obstruction of
the upper airways during sleep, associated with increasing
respiratory efforts, intermittent arterial oxygen desatura-
tion and sleep disruption [1]. It is a prevalent disease, 4e5%
in the general population [2], and is associated with
increased cardiovascular risk and mortality, increased risk
of traffic accidents and increased use of health care re-
sources [1,3].
Continuous positive airway pressure (CPAP) therapy for
OSA was first proposed by Sullivan et al. [4] in 1981 and
since then extensive works confirmed its efficiency in the
long term treatment [5]. A number of studies have exam-
ined outcomes relate to CPAP use and have observed a dose
effect of CPAP therapy in improving symptoms, daytime
sleepiness and quality of life [6e8].
Inadequate adherence remains a major cause of treat-
ment failure [9,10], and when adherence is defined as
greater than 4 h of nightly use, 46e83% of patients have
been reported to be non-adherent [11].
Since treatment adherence is widely recognized as a
critical problem in the OSA treatment in short and even
more so in the long term [12], it is important to determine
factors that could help predict treatment compliance since
it would enable the creation of mechanisms aiming at
improving the long term effectiveness of such treatment.
Although various attempts have been made to predict and
identify factors which predict short and long term compli-
ance, the available data is diverse and conflicting [13e16].
Also, studies have suggested that early therapy adherence
might be of help identifying those who abandon/discon-
tinue or have poor compliance to treatment [17,18].
Nevertheless prospective long-term studies, particularly
using auto-adjusting CPAP (APAP) are still lacking.
This prospective study aimed to determine the long-
term adherence and compliance to APAP treatment in
consecutive patients with moderate and severe OSA and to
evaluate the impact of initial adherence and compliance on
long-term patients.Material and methods
Study subjects
Eighty-eight male patients, referred to the Sleep-Disor-
dered Breathing Clinic, with newly diagnosed moderate/
severe OSA (apnoeaehypopnoea index (AHI) > 20/h),
confirmed by domiciliary sleep study, were included in the
study.Exclusion criteria were established previously:
neoplastic diseases, active infectious diseases, FEV1/
FVC < 70, hypercapnia (PCO2  55 mmHg), and the absence
of national health system. Also, this study was restricted to
male gender, due to the distribution of OSA in the patient
population [2].
The study was approved by the Ethics Committee and all
patients gave written informed consent to participate.
Study design
This is a prospective observational study.
After initiation of APAP treatment, patients had periodic
follow-up appointments at 2 weeks, 6 months and then
annually for at least 5 years. Patient’s compliance to
therapy was assessed using the home ventilator’s memory
card data in each appointment and predictors to treatment
abandonment and poor compliance were evaluated.
Adherence refers to treatment maintenance trough time
and compliance to the daily use evaluated using the per-
centage of days of use and mean time/day.
Methods
An overnight sleep study was performed using a five chan-
nel recording device (AlphaScreen, Vyasis). This device
produces a computerized recording of variations in oronasal
airflow (measured by nasal cannula and thermistor),
abdominal and thoracic respiratory efforts, roncopathy,
body position, wrist actimetry, pulse rate, and arterial ox-
ygen saturation (measured by finger pulse oximetry). The
device estimates the total sleep time from the wrist
actimetry registry, eliminating those periods with high ac-
tivity. It automatically calculates the number of apnoeas
plus hypopneas per hour of estimated sleep time and it also
provides information of desaturations >4% per hour of
estimated sleep time and the cumulative percentages of
sleep time under 90% oxygen saturation.
In all cases, sleep technicians carried out a manual
analysis of the recordings, by counting apnoea and hypo-
pnoea episodes according to guidelines [19], dividing the
total number of these episodes by sleep time in hours, thus
obtaining manual AHI.
Following diagnosis, OSA physiology, symptoms and
consequences were explained to patients as well as the
advantages and possible complications of APAP treatment.
This was performed by the same Respiratory Physician in all
cases.
All patients were prescribed APAP (REMstar Auto,
Respironics Inc., Murrysville, PA, USA) therapy with a mean
minimum pressure of 4 cm H2O and a mean maximum
pressure of 17 cm H2O.
Table 1 Sample characteristics at baseline.
Variable n Z 88
Mean (SD)
Age (years) 53.8 (11.5)
BMI (kg/m2) 33.23 (5.0)
ESS 12.15 (5.3)
AHI (events/h) 52.71 (20.6)
n (%)
Smoking habits
Non-smokers 30 (36.1)
Former smokers 37 (44.6)
Current smokers 16 (19.3)
Hypertension 26 (30.2)
Stroke 16 (18.6)
Acute myocardial infarction 8 (9.4)
Angina 2 (2.3)
Cardiac arrhythmia 2 (2.3)
Employment status
Employed 43 (56.6)
Unemployed 8 (10.5)
Retired 25 (32.9)
Marital status
Married/Living as a couple 54 (68.4)
Living alone (single/divorced/widowed) 25 (31.6)
BMI e body mass index, ESS e Epworth sleepiness scale, AHI e
apnoeaehypopnoea index.
2048 M. van Zeller et al.In Portugal, APAP treatment costs which include delivery
and technical maintenance by domiciliary respiratory care
givers companies, is completely covered by the Portuguese
national health system, therefore treatment was provided
with no additional cost to patients.
Periodic follow-up were conducted at approximately 2
weeks (12 days), 6 months and then annually post-
treatment initiation with evaluation of the clinical symp-
toms and APAP compliance variables (number of hours per
night, percentage of total days of APAP usage), pressure on
90% nighttime (P90) and residual apnoeaehypopnoea index
(AHI) were assessed analysing data from the memory card
of the ventilator.
Compliance to therapy was classified as very good if
patients used APAP more than 90% of days and more than
6 h/night, good if they used between 70 and 90% of days
and more than 4 h/night, and poor if the use was below 70%
of days and/or less than 4 h/night. Those patients who did
not renewed their APAP prescriptions although they kept
treatment indication were classified as abandoning
treatment.
During the medical appointments, whenever necessary
heated humidification was added, nasal corticosteroids
prescribed and masks were changed according to patient’s
preference or to control excessive leak in order to improve
efficacy, comfort and compliance.
The need to maintained APAP treatment and compliance
encouragement was reassured in all visits.
Analysis
Descriptive statistics were generated for the study sample
using means and standard deviation (SD) for quantitative
variables and proportions for categorical variables.
Poisson generalized linear models were used, with the
default natural log link and offset in the variable natural log
follow-up time (t) to estimate incidence rate ratio of
abandoning treatment.
The area under the ROC curve (AUC) was estimated to
assess the discrimination ability of several variables. If the
AUC was less than 0.6 it was consider to have insufficient
discrimination ability, if it was between 0.6 and 0.8 it was
regarded as acceptable and if higher than 0.8 excellent
[20]. The significant level was fixed at 0.05.
Statistical analyses were performed using the software R
2.12.1.
Results
Overall studied population characteristics at baseline are
presented in Table 1.
The total mean time of follow-up was 5.2 (1.6) years,
during which 22 patients (25%) abandoned APAP therapy
within 3.4 (1.5) years. The 66 (75%) patients who remained
under treatment were follow for a mean time of 5.7 (1.1)
years.
The 5-years compliance of patients who maintained
treatment was very good in 77.3%, good in 16.7% and poor in
6.1% of patients. Regarding the risk of poor compliance,
only the poor initial compliance at 12th days and 6th month
was associated with it.The incidence rate ratio of patient’s characteristics,
disease severity and initial compliance (12th days and 6th
months) for abandoning APAP treatment are presented on
Table 2. Patients with poor compliance at 12 days and 6
months had an increased risk of abandoning treatment 5.8
(95%CI: 2.11e15.95) and 14.5 (4.14e51.02) times higher
than those with very good compliance, respectively.
A significant negative association was observed between
risk of abandoning APAP treatment and age [0.96 (95%CI:
0.93e0.99)]. Regarding 12th day compliance, the risk of
abandonment was lower with increase % of days usage [0.63
(95%CI: 0.52e0.75)] and mean time [0.65 (95%CI:
0.51e0.82)] of APAP use. Similar results were observed for
the 6th month compliance (Table 2).
The authors found no relation between initial ESS score
and 5-years APAP abandonment risk nor with disease
severity represented as AHI. Neither smoking habits nor
the presence of comorbidities, employment or marital
status were associated with long term (5-years) APAP
adherence.
Regarding initial compliance (% days of use and mean
time/night) on 12th day and 6th month and age influence
on abandoning treatment we noticed that the ROC AUC
ranged from 0.693 (% days at 12th day compliance) to 0.865
(% days at 6 months) (Table 3), revealing acceptable to
excellent discrimination ability between those who aban-
doned treatment and those who did not.
We found that patients who used APAP less than 83.3%
and 95.4% of days and less than 5.93 and 5.55 mean hours/
day at 12th day and 6th month, respectively, were at higher
risk of abandoning therapy. In fact, the use of APAP lower
than 33% and 57% of days at 12th day and 6th month,
Table 2 Five years risk of abandoning APAP treatment.
Variable RR 95%CI
Age 0.96 0.93e0.99
BMI 1.005 0.926e1.091
ESS initial 0.98 0.91e1.06
AHI 0.997 0.997e1.018
Smoking habits
Non-smokers 1
Former smokers 0.47 0.15e1.44
Current smokers 1.83 0.67e5.06
Any medical comorbidity
Absent 1
Present 1.05 0.43e2.59
Employment status
Unemployed 1
Employed 0.72 0.2e2.54
Retired 0.39 0.09e1.75
Marital status
Married/living as a couple 0.68 0.28e1.66
Living alone (single/
divorced/widowed)
1
12th Day compliance
Very good 1
Good 1.71 0.55e5.29
Poor 5.80 2.11e15.95
Mean hours/day 0.65 0.51e0.82
% Days/10% of days 0.63 0.52e0.75
6th Month compliance
Very good 1
Good 3.64 0.91e14.56
Poor 14.54 4.14e51.02
Mean hours/day 0.59 0.48e0.74
% Days/10% of days 0.70 0.62e0.79
BMI e body mass index, ESS e Epworth sleepiness scale, AHI e
apnoeaehypopnoea index.
Table 3 Likelihood ratio and predictive values of 12th day
and 6th month compliance and age to predict treatment
abandonment.
Cut-off Sens Spec PPV NPV ROC AUC
12th Day compliance
Mean
hours/day
5.93 72.7 78.2 44.2 88.2 0.734b
2.25 9.1 100.0 100.0 76.7
% Days/10%
of days
83.3 45.5 97.0 83.3 84.2 0.693
33.3 9.1 100.0 100.0 76.7
6th Month compliance
Mean
hours/day
5.55 72.7 77.3 51.6 89.5 0.815a
2.50 27.3 100.0 100.0 80.4
% Days/10%
of days
95.4 95.5 65.2 47.7 97.7 0.865a
57.0 31.8 100.0 100.0 81.5
Age 49 59.1 77.3 46.4 85.0 0.70b
a Excellent discrimination ability.
b Acceptable discrimination ability.
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ment abandonment.
Discussion
The full benefit of many effective medications will only be
achieved if patients adhere to prescribed treatment regi-
mens [21].
Among patients with chronic illnesses, approximately
50% do not take medications as prescribed [22]. Hippo-
crates’ exhortation to the physician to “not only be pre-
pared for what is right himself, but also to make the
patient. cooperate” has consistently failed over the years
[23]. It seems that adherence to therapy may vary across
different pathologies and that chronic conditions present
particular difficulties for medication adherence and
persistence [24].
Regarding respiratory diseases, compliance rates of
48e67% have been reported for inhaled therapy in Asthma
and COPD [25,26] and similar values have been indicated
for long term oxygen therapy (50e65%) [27] and nebulizers
in COPD (50e57%) [28].McArdle et al. [29] reported that 68% of patients
continued treatment after five years, but long-term
adherence to both CPAP and particularly APAP is scarce in
the literature and very heterogeneous since different
criteria have been used to define it. The most widely used
definition of nPAP adherence is a minimum of 4 h/day for at
least 70% of days [30,31].
In our study 75% of patients maintained treatment after 5-
years of follow-up and the majority of patients who main-
tained treatment had very good (77.3%) or good (16.7%)
compliancee 94% of patients used it more than 4 h/day for at
least 70% of days [32]. Previous studies performed in Portugal
reported distinct patterns of adherence and compliance. A
study reported that 15.6% of patients had discontinued
treatment and only 54% of patients were classified as
compliant within the first year of follow-up [33]. Different
results were presented by Soares Pires et al.34 in which 27.7%
patients dropped out within the first 6 months of therapy, but
those who kept the APAP device had a median use of 88.3% of
days and 6.02 h/night at 6 months of follow-up.
Interventions to improve treatment compliance had
been analysed and technical aspects had been evaluated as
well [35,36]. Autotitration and other new therapeutic mo-
dalities have been associated with improvements in patient
comfort [37]. However, most authors have reported similar
adherence rates for APAP and fixed CPAP [35].
Various factors that are likely to influence adherence
have been evaluated, including age [38], gender, socio-
economic factors [39], and disease and symptoms severity
[29,40,41].
It is important to determine factors that could help to
predict compliance to treatment since it would enable the
creation of mechanisms aiming at improving long term
effectiveness of such treatment or supporting the decision
to suspend it. This is particularly important at a time of
financial austerity affecting healthcare services in Portugal
and worldwide.
Interestingly, we found that age and particularly com-
ponents of initial compliance (% days of use and mean time/
day), as soon as 12 days have the ability to predict future
levels of adherence and the risk to abandon treatment.
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demographic, clinical and polysomnographic data is diffi-
cult [42].
Previous studies have showed that data obtained after a
2-week trial can predict compliance at one year [43], and
has been stressed that initial compliance might be a pre-
dictor of long term adherence/treatment continuance [18].
Also, recently, Ghosh [17] proposed a simple prediction
equation that uses data after a two week CPAP trial to
identify long-term poor compliance.
Our study, being prospective and with a higher time of
follow-up (5-years), reinforces this information, high-
lighting the importance of initial adherence as soon as 12
days.
This is hugely relevant since it suggests that the main
focus should be on the first appointment after diagnosis and
that probably explaining OSA physiology, symptoms and
consequences as well as the advantages and possible
complications of APAP treatment is determinant and should
be done as soon as possible.
This study also raises an ethical and economic question
since in Portugal patients have no additional costs with
APAP treatment which is totally supported by the National
Health Care System. We found that APAP use lower than
33% and 57% of days at 12th day and 6th month, respec-
tively, had high specificity (w100%) to detect treatment
abandonment and is in fact lower than the adherence goals
usually used for treatment efficacy e should we insist
longer to convince patients to be more compliant and to
adhere?
A predictor of treatment abandonment and poor
compliance should be collected early on in the process,
nevertheless, we also analyse the impact of 6-months
compliance in long term adherence since we have a long
period of follow-up and that possible interventions to
enhance adherence are developed within the first weeks
and months. We thought that a 6-month evaluation could
be considered as a “last chance performance” for patients
especially since in Portugal, the treatment is supported by
the National Health System, and prescriptions have to be
revalidated by a respiratory physician every 3-month, cor-
responding the 6-months evaluation to a second prescrip-
tion renewal. If it is legitimate to give patients a second
opportunity at 3-months evaluation, considering the results
found in this study it would not be correct to do so at 6-
months (second prescription renewal) regarding costs and
potential benefits.
It has been stressed in the literature [44,45] that edu-
cation plays an important role in adherencedinformed
patients tend to be motivated patients. The use of educa-
tional sessions for patients seems to have good results [34]
although the durability of different strategies to enhance
adherence is still under debate [12]. In a previous study
referring to the impact of a group education session on
APAP compared to patients who had not had it, we found
increased adherence to APAP at 6 months [36]. Neverthe-
less, when the same patients were reevaluated the signif-
icant impact of the educational session vanished at 12th
months of follow-up.
In the present study, no educational sessions were made
as described in the Methods section, as the authors thought
this would be a way of assessing adherence without furtherintervention, information was given about disease and its
treatment to patients during each appointment. Never-
theless, patients with 12th day poor compliance might be
selected for early intervention and afterwards, according
to its impact, it could be decided if it was worthy to
maintain treatment. Such strategy would require further
studies.
We found a high incidence of patients with past medical
history including stroke (18.6%) and acute myocardial
infarction (9.4%). Previous studies reported that during a
seven-year follow-up period, cardiovascular disease was
present in 36.7 percent of patients with obstructive sleep
apnea [46]. Also, other study including OSA patients noted a
previous medical history of myocardial infarction in 8.1
percent and stroke in 7.1 percent [47].
Over the last decade, epidemiologic and clinical
research has consistently supported the association of OSA
with increased cardiovascular morbidity and mortality.
Such evidence prompted the American Heart Association to
issue a scientific statement describing the need to recog-
nize OSA as an important target for therapy in reducing
cardiovascular risk [48].
As potential limitations of this study, the authors refer
the fact that the OSA diagnosis was based on a domiciliary
sleep study instead of attended polysomnography. Never-
theless, both have been previously compared, showing that
the first one is a viable, accurate, satisfactory, useful and
cost effective way of diagnosing OSA [49]. Also, the study
design aimed to obtain an homogeneous sample of patients,
having all patients, regardless their symptoms or comor-
bilities, undoubtful indication for nPAP therapy. Further-
more these consecutive patients were all diagnosed and
followed by the same physician, avoiding inter-individual
bias. Male patients were enrolled since OSA prevalence is
higher in this group [2] so it would be more efficient to
include a significant number of patients to get results.
Moreover, the inclusion of both gender patients is an
important aspect when discussing treatment adherence and
could be seen as a limitation of this study. It is a downfall
since other studies have showed conflicting evidence
regarding of gender in long term compliance [16,38,50].
Also our strategy for APAP initiation relied on the use of
initial pressures chosen empirically based in our center
previous experience which might be argued. The choose of
interfaces and decision to prescribe medication for nasal
symptoms was performed in a patient-to-patient basis,
without any specific protocol but intended to satisfy the
patient resulting in a very practical and clinical approach.
Initial symptom evaluation performed using ESS was not
related to long term compliance neither to treatment
abandonment. The authors did not evaluate the 12-day
change in sleepiness scale since the initial treatment period
(12 days) was considered very short and possibly not enough
to achieve ESS scores to draw.
On the other hand we believe that the adherence criteria
used, classifying compliance in three distinct groups (very
good, good and poor) was beneficial since more recent find-
ings [8,51] point out that adherence goals usually used (>4 h
per day for at least 70% of days)may be outdated and this will
allow future comparisons within studies.
In this study, a reasonable proportion of patients (75%)
adhered to 5-years APAP treatment and had very good to
5-Years APAP adherence in OSA patients 2051good compliance. Age and initial compliance (% days of use
and mean hour/day) have the ability to predict future
adherence and the probability of treatment abandonment,
as soon as 12 days and 6 months after initiation. First im-
pressions seem to last.Conflict of interest
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